Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar.
Mol Biol Rep. 2022 Mar;49(3):2321-2324. doi: 10.1007/s11033-022-07183-w. Epub 2022 Jan 31.
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
大量研究表明 CVD、2 型糖尿病（T2DM）和 COVID-19 病理之间存在相似之处，这加重了感染 COVID-19 的患者原有的并发症，并可能使感染过程恶化。由于钠-葡萄糖共转运蛋白-2（SGLT-2）抑制剂在降低心肾疾病严重程度方面的疗效，最近引起了广泛关注。SGLT-2 抑制剂在 COVID-19 患者中的作用尚不清楚，特别是因为 SGLT-2 抑制剂会改变肾素-血管紧张素-醛固酮系统（RAAS）级联反应的活性，其中包括 ACE-2，这是 SARS-CoV2 的主要细胞进入受体。一项名为 DARE-19 的研究旨在揭示 SGLT-2 抑制剂治疗对合并疾病并发症和并发 COVID-19 结局的影响，但未显示出统计学意义。然而，需要进一步研究以提供确凿的临床发现。
